Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Enterprise Value (2016 - 2025)

Avalo Therapeutics' Enterprise Value history spans 12 years, with the latest figure at -$98.3 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 517457.89% year-over-year to -$98.3 million; the TTM value through Dec 2025 reached -$98.3 million, down 517457.89%, while the annual FY2025 figure was -$98.3 million, 517457.89% down from the prior year.
  • Enterprise Value reached -$98.3 million in Q4 2025 per AVTX's latest filing, down from -$84.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$14000.0 in Q2 2022 to a low of -$125.0 million in Q1 2025.
  • Average Enterprise Value over 5 years is -$41.1 million, with a median of -$27.6 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: soared 99.97% in 2022, then plummeted 517457.89% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$51000.0 in 2021, then skyrocketed by 70.59% to -$15000.0 in 2022, then crashed by 49333.33% to -$7.4 million in 2023, then skyrocketed by 99.74% to -$19000.0 in 2024, then tumbled by 517457.89% to -$98.3 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Enterprise Value are -$98.3 million (Q4 2025), -$84.7 million (Q3 2025), and -$71.0 million (Q2 2025).